Question 1

How does LL-37 relate to vitamin D?

Accepted Answer

The CAMP gene that encodes hCAP18, the precursor of LL-37, is a direct target of the vitamin D receptor: 1,25-dihydroxyvitamin D3 strongly up-regulated it in myeloid cells. In human macrophages, Toll-like receptor activation triggered a vitamin D–dependent cathelicidin response that killed intracellular Mycobacterium tuberculosis, and sera low in 25-hydroxyvitamin D supported this response poorly. This suggests vitamin D status may influence innate antimicrobial defense, but it does not establish a specific target level for raising LL-37.

Question 2

Can bacteria develop resistance to LL-37?

Accepted Answer

Because LL-37 acts largely on microbial membranes rather than a single protein target, resistance is often assumed to develop more slowly than with conventional antibiotics, but this has not been settled clinically. Some bacteria have mechanisms that can reduce susceptibility to host antimicrobial peptides, and LL-37's direct killing activity against some species, such as Pseudomonas aeruginosa, is relatively weak in laboratory tests.

Question 3

Why is LL-37 not yet widely available as a drug?

Accepted Answer

LL-37 is a 37-residue peptide, which makes it more complex to manufacture and formulate than small molecules, and clinical development has so far been limited to small topical wound trials. In the first-in-human leg ulcer trial, the highest concentration did not outperform placebo, showing that dose finding is still incomplete. It remains an investigational, research-only compound.

Question 4

Can LL-37 help with biofilm infections?

Accepted Answer

In laboratory studies, LL-37 inhibited Pseudomonas aeruginosa biofilm formation at 0.5 µg/mL, far below the concentration needed to kill the bacteria (64 µg/mL), by reducing bacterial attachment, stimulating twitching motility and dampening quorum-sensing genes; it also affected existing biofilms. This makes it interesting for chronic wound infections, but anti-biofilm benefit has not been demonstrated in human trials.

Question 5

How does LL-37 compare to Thymosin Alpha-1 for immune support?

Accepted Answer

They act on different parts of the immune system. LL-37 is an innate-immunity peptide with direct antimicrobial activity that also recruits immune cells. Thymosin alpha-1 is studied mainly as a modulator of T-cell–mediated immunity. No study has compared or combined them.

Question 6

Can LL-37 be used alongside antibiotics?

Accepted Answer

Combining LL-37 with antibiotics is a research question rather than a clinical practice. Because LL-37 can inhibit biofilm formation at low concentrations in the laboratory, it has been proposed as a way to improve antibiotic access to biofilm bacteria, but no human combination trial has been completed.

Question 7

Is LL-37 relevant for gut health?

Accepted Answer

LL-37 is expressed by epithelial cells of the gastrointestinal tract as part of the innate immune barrier, and the CAMP gene is induced by vitamin D in colon cell lines. Whether supplemental LL-37 helps any gut condition has not been tested in human trials.

Question 8

How does LL-37 promote wound healing beyond its antimicrobial effects?

Accepted Answer

In laboratory and animal studies LL-37 stimulated keratinocyte migration via heparin-binding EGF–mediated EGFR transactivation, induced angiogenesis via FPRL1 on endothelial cells (mice lacking the mouse equivalent showed reduced wound vascularization), and recruited neutrophils, monocytes and T cells via FPRL1. In the first-in-human venous leg ulcer trial, topical LL-37 at 0.5 and 1.6 mg/mL improved healing compared with placebo, while 3.2 mg/mL did not.

Origin / Manufacturer	Synthetic (recombinant or solid-phase synthesis)
Active Components	LL-37 peptide (37 amino acids)Bacteriostatic water (for reconstitution)
Storage	Lyophilized: -20°C recommended. Reconstituted: 2–8°C
Shelf Life	Lyophilized 18+ months at -20°C; reconstituted 14 days refrigerated
Form Factor	Lyophilized powder (1 mg or 5 mg vial)

LL-37

Specifications

Clinical Evidence

Frequently Asked Questions

Sources & References

Related Peptides

BPC-157

KPV

Thymosin α1